Over 400 clients have taken advantage of ChemBridge's discovery chemistry portfolio, including all major pharmaceutical companies in the US, Europe, and Japan.

Our clients include Pfizer, Merck, Roche, AstraZeneca, Bristol-Myers Squibb, Amgen(Tularik), Kirin, and Sumitomo Pharmaceuticals, all of whom have publicly announced major discovery chemistry or combinatorial chemistry deals with ChemBridge.

Here's what some of our clients have to say about our products and services:

“We are very pleased with the quality of the GPCR-focused library, particularly since the library helped us to resurrect several projects that we had previously dropped due to lack of leads.”

Jeremy Caldwell, Ph.D.
Director of Molecular and Cellular Biology
Genomics Institute of the Novartis Research Foundation

“After considerable assessment, we found that their (PHARMACophore) libraries were complementary to AstraZeneca's own collection of compounds and we look forward to utilizing ChemBridge's specialist capability in our drug discovery programs."

Michael Cox, Ph.D.
Director of HTS & Compound Management
AstraZeneca Pharmaceuticals

"We sought small molecules that were the inhibitors of polyglutamine(polyQ) aggregation, implicated in CAG-triplitv repeat neurodegenerative disorders,  including Huntington's disease(HD). We have utilized a cell-based aggregation assay to screen the ChemBridge DIVERSet™ Library to identify hit-compounds. These hits were optimized with the ChemBridge HIT2LEAD service. Within the Chembridge collection, we identified a compound with nanomolar activity in an in vitro model of HD, and efficacy in an in vivo model for HD. The aggregation inhibitors identified through the efforts represent strong lead candidates for the development of therapeutics for human polyQ disorders."

Aleksey Kazantsev, Ph.D.
Assistant Professor
Harvard Medical School Director
High Throughput Screening Laboratory
MassGeneral Institute for Neurodegenerative Disease

top of the page